

Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024

Asarina Pharma AB (publ) ("Asarina" or the "Company") announced on 13 September 2024 that the Company has applied for the delisting of its shares from Nasdaq First North Growth Market in Stockholm. Nasdaq Stockholm has approved the Company's application for delisting.

The board of Asarina decided on 13 September 2024 to apply for the delisting of the Company's shares from the Nasdaq First North Growth Market in Stockholm. According to a decision from Nasdaq Stockholm, Asarina's shares will be delisted from the Nasdaq First North Growth Market. The last day of trading in the Company's shares will be 1 October 2024.

For further information, please contact:

Peter Nordkild, CEO

Tel.: +45 25 47 16 46

Email: peter.nordkild@asarinapharma.com

About Asarina Pharma

Asarina Pharma AB (publ) is a Swedish biotechnology company. The company was founded in 2006 and the share has been traded since September 2018 on the Nasdaq First North Growth Market.

Asarina Pharma AB (publ) is based in Solna. Asarina Pharma AB (publ) is listed on the Nasdaq First North Growth Market. The company thus follows the regulations that apply to First North. The company's Certified Adviser is Carnegie Investment Bank AB (publ).

For further information see our website: www.asarinapharma.se.

Attachments

[Asarina Pharma AB \(publ\) shares to be delisted and the last day of trading is 1 October 2024](#)